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Abstract
Background: The trans-neuronal propagation of tau has been implicated in the progression of tau-mediated
neurodegeneration. There is critical knowledge gap in understanding how tau is released and transmitted, and how
that is dysregulated in diseases. Previously, we reported that lysine acetyltransferase p300/CBP acetylates tau and
regulates its degradation and toxicity. However, whether p300/CBP is involved in regulation of tau secretion and
propagation is unknown.
Method: We investigated the relationship between p300/CBP activity, the autophagy-lysosomal pathway (ALP) and
tau secretion in mouse models of tauopathy and in cultured rodent and human neurons. Through a high-through-put
compound screen, we identified a new p300 inhibitor that promotes autophagic flux and reduces tau secretion. Using
fibril-induced tau spreading models in vitro and in vivo, we examined how p300/CBP regulates tau propagation.
Results: Increased p300/CBP activity was associated with aberrant accumulation of ALP markers in a tau transgenic
mouse model. p300/CBP hyperactivation blocked autophagic flux and increased tau secretion in neurons. Conversely,
inhibiting p300/CBP promoted autophagic flux, reduced tau secretion, and reduced tau propagation in fibril-induced
tau spreading models in vitro and in vivo.
Conclusions: We report that p300/CBP, a lysine acetyltransferase aberrantly activated in tauopathies, causes
impairment in ALP, leading to excess tau secretion. This effect, together with increased intracellular tau accumulation,
contributes to enhanced spreading of tau. Our findings suggest that inhibition of p300/CBP as a novel approach to
correct ALP dysfunction and block disease progression in tauopathy.
Keywords: Tauopathy, Tau secretion, Tau spreading, Autophagy-lysosomal pathway, p300/CBP
Background
Tauopathies, including Alzheimer’s disease (AD) and fronto-
temporal lobe degeneration with tau inclusions, are neurode-
generative diseases characterized by deposition of
neurofibrillary tangles composed of the microtubule-
associated protein tau in the brain. Tau pathology spreads in
a stereotypic pattern, which is used to stage the disease [1, 2].
Cell-to-cell transmission of pathogenic tau species may ac-
count for the spreading of tau pathology in the brain [3–5],
however, the process by which tau transmits between neu-
rons is poorly understood.
Homeostatic levels of tau are maintained by the
autophagy-lysosomal pathway (ALP) and the ubiquitin-
proteasomal system (UPS). Impairment of these de-
gradative systems leads to intracellular tau accumulation,
neuronal deficits, and aggregate formation [6]. Tau is
also present in the cerebrospinal fluid (CSF) and intersti-
tial fluid, and in the conditioned medium of neuronal
culture. Extracellular tau species can be toxic to neurons
[7, 8] and more importantly, may serve as pathogenic
“seeds” to be taken up by surrounding neurons, enabling
prion-like propagation [9, 10]. Rather than being
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passively released after neuronal death, tau is actively
secreted by live neurons [11, 12]. Tau lacks a signal
peptide, and may be exported by an unconventional
secretion pathway [11, 13], that overlaps with ALP [14,
15]. Thus, autophagy—a key mechanism for tau degrad-
ation—could also play a role in tau secretion and
propagation.
p300, a lysine acetyltransferase for numerous nuclear
and cytosolic proteins, is a master regulator of Alzheimer’s
disease progression [16]. Previously, we showed that p300
and its close homolog CBP directly acetylate tau, and that
hyperacetylation of tau caused by increased p300/CBP
activity promotes tau accumulation [17, 18]. Inhibition of
p300/CBP reduces tau accumulation, tau pathology, and
cognitive deficits in tau transgenic mice, highlighting a
critical role for p300/CBP in tauopathies [17]. However,
whether p300/CBP also contributes to tau secretion and
propagation is unknown.
In this study, we show that p300/CBP activity is ele-
vated in the setting of tauopathy, and that this is associ-
ated with dysfunction of ALP. Using HEK293T cell
reconstitution and neuronal culture, we investigated the
relationship between p300/CBP, autophagic flux and tau
secretion. We performed a high throughput screen for
new p300 inhibitors, and identified a compound that has
strong effect on reducing tau secretion. Using this
compound and genetic manipulations, we further show
that p300/CBP inhibition affects tau propagation in both
in vitro and in vivo tau spreading models.
Materials and methods
Primary antibodies and chemicals
Antibodies for p300 (N-15, SCBT), CBP (Cell Signaling),
acetylated H3/K18 (Abcam), H3 (Cell Signaling), LC3B
(Acris), LC3A (Novus Biologicals), p62/SQSTM1 (Novus
Biologicals), GAPDH (Sigma), actin (DSHB), Tau-5 (Bio-
Source), HT7 (Thermo Fisher), BT2 (Thermo Fisher),
AT8 (Thermo Fisher), caspase-3 (Cell Signaling), α-
tubulin (Abcam), MAP-2 (Millipore), GST-D2 (Cisbio),
and europium cryptate-labeled anti-rabbit IgG-EuK (Cis-
bio) were purchased. Ac-tau/K174 antibody (AC312)
and ac-tau/K274 antibody (mAB359) were produced and
characterized as described previously [17,69]. The MC1
antibody was a gift from Dr. Peter Davies (Feinstein In-
stitute). CTB (Sigma), NH4Cl (Sigma), Leupeptin
(Sigma), vinblastine (Sigma), rapamycin (Invivogen), and
Bafilomycin A1 (Invivogen) were purchased.
Human samples
CSF samples were obtained from 13 patients with
Alzheimer’s disease (AD) and 14 cognitively normal
participants (Additional file 1: Table S1). Patients
were recruited through the research programs: Fron-
totemporal Dementia: Genes, Images and Emotions,
4-Repeat Tauopathy Neuroimaging Initiative (4RTNI)
and Alzheimer’s Disease Research Center (ADRC) at
the University of California, San Francisco (UCSF).
All patients received a comprehensive neurological
history, physical, structured caregiver interview and
neuropsychology assessment. Diagnosis was made by
consensus panel, utilizing the standard diagnostic cri-
teria for AD and PSP [19, 20]. Cognitively normal
healthy patients were recruited through the Larry L.
Hillblom Aging Study at UCSF. The eligibility criteria
included ages 60–100, with no significant subjective
memory complaints, no functional impairment, a
Clinical Dementia Rating (CDR) of 0, no diagnosis of
mild cognitive impairment, and a Mini-Mental State
Exam (MMSE) score of ≥26.
CSF collection and processing was performed accord-
ing to the Alzheimer’s Disease Neuroimaging Initiative
protocol. CSF was obtained by lumbar puncture using a
25-gauge needle and collected in 10-mL polypropylene
tubes. Within 1 h, CSF was centrifuged at 2000 g for 10
min at 4 °C, transferred to new polypropylene tubes and
stored at − 80 °C until analysis.
Protein purification
DNA encoding a fragment of p300 (aa 1815–1910),
including the PHD, catalytic (HAT), ZZ and TAZ2
domains, was cloned into a pET24b vector. The plasmid
was transformed into the E. coli Rosetta BL21 strain
(Invitrogen). Frozen cell stock was streaked onto a
Kanamycin (50 μg/mL) plate and grown overnight. One
colony was picked and grown in a starter culture and
used to inoculate 6 L of 2X YT media. Upon log-phase
growth (OD ~ 0.6–0.8), expression was carried out by
overnight induction with 0.2 mM IPTG at 16 °C. The
cells were harvested at 5000 rpm for 15min and resus-
pended in 100 mM NaCl, 100mM Tris pH 8.0 and dis-
rupted through a microfluidizer. The lysate was then
spun down at 20,000 rpm for 45 min and filtered. Protein
was purified in two steps by Ni affinity chromatography
and anion exchange chromatography using an ÄKTA
system (GE Healthcare). The lysate was then loaded
onto a 1 mL HisTrap HP column (GE Healthcare). The
column was subsequently washed with 10% B and 20% B
and eluted with 100% B. The Ni elution fraction was
diluted 10-fold with 20 mM Tris pH 8.0 and was
loaded onto a 1 mL HiTrap Q column (GE Health-
care). Elution was carried out by a 0–100% B gradient
over 20 column volumes collecting 1.0 mL fractions.
Flow rates were typically held constant at 1.0 mL/min
or lowered if the pressure exceeded the limit of the
column accordingly. HitrapQ fractions were further
polished on gel filtration column superdex 200 16/60
in 20 mM Tris pH 8.0, 150 mM NaCl. GST-tau was
produced as previously reported [18].
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HTS of p300 inhibitors based on the homogeneous time-
resolved fluorescence assay
50 nL of compound (final 0.5% DMSO) was added to
5 μL (final 6 nM) GST-tau in a 384-well plate. The reac-
tion was initiated by adding 5 μL (final 1 nM) p300,
followed by 1 h incubation at RT. At the end of the reac-
tion, 10 μL/well of quench/detection mixture contain-
ing 10 nM mAB359, 2.4 nM donor (anti-rabbit IgG-
EuK), 3.6 nM acceptor (anti-GST-D2), and 25 μM ana-
cardic acid (a known p300 inhibitor as the quench re-
agent) in detection buffer (50 mM sodium phosphate,
pH 7.9, 0.8M KF) was added. The final mixture was then
incubated at RT for another 2 h. After incubation, signal
was read on EnVision Multilabel Plate Reader (PerkinEl-
mer; ex: 340 nm, em: 665/620 nm). DMSO and anacardic
acid served as negative and positive controls, respect-
ively. Percent inhibition was calculated as (FRET signal
of DMSO-FRET signal of compound)/(FRET signal of
DMSO-FRET signal of anacardic acid) × 100%.
To rule out compounds that suppress FRET through
mechanisms other than inhibition of p300, a counter
screen was performed in which compounds were added
after 1 h incubation of the enzymatic reaction, followed
immediately by the subsequent quench/detection. Any
compounds that suppressed the FRET signal were con-
sidered false positives.
Orthogonal MMBC assay
The thiol-reactive dye MMBC ([10-(2,5-dihydro-2,5-
dioxo-1H-pyrrol-1-yl)-9-methoxy-3-oxo-,methyl ester
3H-naphthol (2,1-b) pyran-S-carboxylic acid, known as
ThioGlo 1] was used to detect CoA, the product of the
acetylation reaction. Once MMBC reacts with CoA, it
becomes fluorescent with excitation wavelength at 379
nm and emission wavelength at 513 nm. The assay was
performed with a final volume of 50 μL in assay buffer
(100 mM HEPES, pH 7.5, 0.01% Triton-X100, 500 μM
TCEP). Compounds of various concentrations were
added to the mixture of 200 nM p300, 0.6 μM Tau,
100 μM Ac-CoA, and 250 μM MMBC. The reaction
progress was continuously monitored on plate reader
Flexstation III (Molecular Devices) for 1 h. The slopes of
the linear portion of the reaction were used to calculate
the percentage of inhibition.
Differential scanning Fluorimetry
1 μM p300 with 5X syprorange was incubated with
25 μM, or 50 μM 37892 in the assay buffer. The Tm of
p300 was monitored on real-time PCR machine Strata-
gene Mx3005p.
HEK293T cell culture
HEK293T cells cultured in Dulbecco’s Modified Eagle’s
medium (DMEM) with 10% fetal bovine serum were
transfected with expression vectors encoding FLAG-
tagged full-length hTau and myc-tagged p300, or empty
vector, using lipofectamine 2000 (Life Technology). For
mCherry-GFP-LC3 reporter, HEK293T cells were in-
fected with lentivirus expressing mCherry-GFP-LC3, and
a single clone of infected cells with moderate expression
was isolated to establish the reporter line.
Primary neuronal cultures and Lentiviral or AAV
infections
Primary neuronal cultures were established from cortices of
Sprague-Dawley rat (Charles River Laboratories) or mouse
pups on postnatal day 0 or 1. Purified cells were plated at
600,000 cells/ml in Neurobasal medium supplemented with
B27 (Invitrogen) on poly-ornithine-coated plates. All exper-
iments were performed at 11–14 days in vitro (DIV) unless
noted otherwise. Lentivirus was generated, purified, and
used for infection as described [22]. Briefly, recombinant
lentivirus was produced by cotransfection of the shuttle
vector (pRRL), two helper plasmids, delta8.9 packaging vec-
tor, and VSV-G envelope vector into HEK293T cells and
purified by ultracentrifugation [23]. AAV viral vectors ex-
pressing P301S tau were generated and purified from Viro-
vek, Inc. (Hayward, CA). All drug treatments and analyses
were performed at DIV 10–13 days.
Differentiation of human iPSC–derived neurons
Human iPSC-derived neurons were differentiated with a
simplified two-step protocol (pre-differentiation and matur-
ation), as described previously [41]. Briefly, iPSCs (WTC11
line) containing a Ngn2 transgene integrated into the
AAVS1 locus were pre-differentiated in Knockout Dulbec-
co’s modified Eagle’s medium (KO-DMEM)/F12 medium
containing growth factors and doxycycline. After pre-
differentiation, the neuronal precursor cells were matured
in maturation medium containing 50% DMEM/F12, 50%
Neurobasal-A medium with all the growth factors. Human
neurons were assayed at 5–8weeks post-differentiation.
Tau secretion assay
Neuronal tau secretion assay was performed on mature neu-
rons (DIV 11–14 for primary neurons, 5–8weeks old for hu-
man iPSC-derived neurons). Fresh artificial cerebrospinal
fluid (ACSF) containing NaCl (140mM), KCl (5mM), CaCl2
(2.5mM), MgCl2 (2mM), HEPES (10mM) and glucose (10
mM) was added to neurons to replace the original medium
(neurobasal medium with B27 supplement). After 3 h incu-
bation at 37 °C, the conditioned medium was harvested and
centrifuged at 8000 RPM to remove cell debris, and sub-
jected to tau ELISA analysis to quantify the amount of extra-
cellular tau. To analyze the truncation of extracellular tau,
the conditioned medium was concentrated by 12.5-fold using
Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-
3K membrane (Millipore), and subjected to immunoblot
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analysis. For HEK293T cells, serum-free DMEM was used to
replace post-transfection medium, and incubated at 37 °C for
24–48 h. The conditioned medium was harvested and centri-
fuged at 8000 RPM to remove cell debris, and concentrated
by 25-fold using Amicon Ultra-0.5 Centrifugal Filter Unit
with Ultracel-30K membrane (Millipore). The concentrated
medium was subjected to immunoblot analysis to quantify
the amount of extracellular t-tau, p-tau and ac-tau. Tau se-
cretion was calculated by normalizing levels of extracellular
tau (in the conditioned medium) to the intracellular tau (in
the lysate). LDH assay (Promega) was used to monitor cell
toxicity per manufacturer’s protocol.
Homogenization of cells and tissues for Immunoblot
analyses
HEK293T cells or mouse brain tissues were homoge-
nized in RIPA buffer containing protease inhibitor cock-
tail (Sigma), 1 mM phenylmethyl sulfonyl fluoride,
phosphatase inhibitor cocktail (Sigma), 5 mM nicotina-
mide (Sigma) and 1 μM trichostatic-A (Sigma). Neurons
were homogenized in N-Per buffer (Thermo Fisher) con-
taining all the inhibitors as above. Mouse brain tissues
were sonicated after homogenization. Lysates were cen-
trifuged at 14,000 RPM at 4 °C for 15 min. Supernatants
were collected and protein concentrations were deter-
mined by the BCA assay (Thermo Fisher). Pellets con-
taining the nuclei were washed with 1/3 volume of the
lysis buffer, and used for histone extraction by overnight
incubation with HCl (0.24 N). The same amount of pro-
tein was resolved on a 4–12% SDS-PAGE gel (Invitro-
gen), transferred to PVDF membrane (Bio-Rad), and
probed with appropriate antibodies. Bands in immuno-
blots were visualized by enhanced chemiluminescence
(Pierce) and quantified by densitometry and ImageJ soft-
ware (NIH). Representative blots from same gel/mem-
brane are shown and compared in the same figure.
Samples from non-adjacent lanes are separated by a line.
ELISA
AcH3K18 ELISA was performed using EpiQuik Global
Acetyl Histone H3K18 Quantification Kit (Colorimetric)
(EpiGentek). CSF samples were concentrated by 10-fold
using Amicon Ultra Centrifugal Filter Unit with Ultracel-
3K membrane (Millipore). Mouse β-tubulin ELISA was per-
formed using Mouse TUB β ELISA kit (MyBiosource
MBS723313), according to manufacturer’s protocol. Mouse
Aβ40 and Aβ42 ELISA was performed using Amyloid β 40
and Amyloid β 42Mouse ELISA Kit (Thermo Fisher), accord-
ing to manufacturer’s protocol. Sensitive Tau ELISAs were
adapted and modified according to previous reports [24, 25]
and as described previously [41]. Briefly, mouse monoclonal
antibody BT2 or HT7 was used for capture. The respective
analytes were detected with alkaline phosphatase–con-
jugated mouse monoclonal antibody against Tau5
(BioLegend). Recombinant full length hTau (rPeptide)
was used to generated standard curves for each assay.
The CDP-Star substrate (Invitrogen) was used as
chemiluminescent alkaline phosphatase substrate.
Immunofluorescence staining
Cells grown on coverslips were washed with phosphate-
buffered saline (PBS) and fixed in fresh 4% paraformal-
dehyde, and permeabilized with 0.1% Triton X-100.
Coverslips were washed in PBST (phosphate-buffered sa-
line, 0.01% Triton X-100), and incubated for 1 h in
blocking solution containing PBST and 5% normal goat
serum. The cells were then incubated in blocking solu-
tion containing primary antibody overnight at 4 °C,
followed by incubation with secondary antibody for 1 h.
Primary antibodies include MC1 (1:500), MAP2 (1:800)
and acH3K18 (1:1000). Secondary antibodies include
fluorescein-labeled goat anti-mouse IgG and goat anti-
rabbit IgG (1:500, Vector Laboratories). Hoechst (Thermo
Fisher) was used to label the nuclei. Images were acquired
by Leica microscope (DM5000 B) and analyzed by Micro-
Manager software (UCSF, San Francisco, CA). For
p300F/F/CBPF/F and p300F/+/CBPF/+ neurons, a fully auto-
mated ArrayScan high-content system (Thermo) was used
to acquire images and quantify MC1 signal and neuronal
health parameters.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from p300F/F/CBPF/F primary
neurons with the Direct-zol™ RNA MiniPrep kit (Zymo),
and the remaining DNA was removed by incubation
with RNase-free DNase (Zymo). Purified messenger
RNA was then converted to complementary DNA by the
TaqMan reverse transcription (RT) kit (Applied Biosys-
tems). Quantitative RT-PCR was performed on the ABI
7900 HT sequence detector (Applied Biosystems) with
SYBR Green PCR master mix (Applied Biosystems). The
average value of three replicates of each sample was
expressed as the threshold cycle (Ct), at which the fluores-
cence signal starts to increase rapidly. Then, the difference
between the Ct value for hTau and the Ct value for mouse
GAPDH (ΔCt = Ct (hTau)-Ct (GAPDH)) was calculated
for each sample. The relative levels of gene expression for
each sample was determined by 2-ΔCt and expressed as
the fold change. The following primers were used for
quantitative RT-PCR: hTau (forward, 5′-GTTGGGGGAC
AGGAAAGATCAG-3′; reverse, 5′-CCGGGAGCTC
CCTCATC-3′), mouse GAPDH (forward, 5′-GGGAAG
CCCATCACCATCTT-3′; reverse, 5′-GCCTTCTCCA
TGGTGGTGAA-3′).
Tau purification and fibrilization
Myc-tagged repeat domain (K18) of P301L tau was
expressed in Terrific Broth media containing sodium
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chloride (500 mM) and a small-molecule chaperone,
betaine (10 mM), to improve expression and minimize
degradation. Expression was induced with 200 μM IPTG
for 3.5 h at 30 °C. tau was purified as described [26].
Purified tau was dialyzed overnight at 4 °C into aggrega-
tion assay buffer (Dulbecco’s PBS pH 7.4, 2 mM MgCl2,
1 mM DTT). Aggregation of tau (20 μM) was induced
by the addition of a freshly prepared heparin sodium
salt solution (Santa Cruz) at a final concentration of
88 μg/ml. Tau fibril samples were labeled with Alexa
Fluor 647 NHS ester (Molecular Probes) at 1:40M ra-
tio of dye:tau monomer for 1 h at room temperature.
Samples were centrifuged at 100,000 g for 1 h at 4 °C
to remove unreacted free dye. Pellets containing tau
fibrils were resuspended in Dulbecco’s PBS, pH 7.4, 2 mM
MgCl2. Tau fibril concentrations were quantified by SDS-
PAGE with a set of tau monomer standards.
In vitro fibril-induced tau spreading model
The in vitro fibril-induced tau spreading model was
adapted and modified from previously described [27].
Briefly, primary neurons cultured on coverslips were in-
fected with AAV-P301S hTau on DIV3, and synthetic
tau fibrils (K18/P301L, 100 nM) were added to the
medium on DIV5. Neurons without AAV infection
(AAV-) and neurons treated with PBS instead of fibrils
were included as negative controls. Neurons were incu-
bated with the fibrils for 7–10 days. To test the effect of
compound treatment, drugs were added to the culture
medium together with the fibrils, and replenished once
after 3 days. Immunofluorescence staining using the
MC1 antibody (1:500) was performed to detect tau ag-
gregates. Briefly, neurons grown on coverslips were
washed with fresh medium containing 0.01% trypsin,
and fixed in fresh 4% PFA with 0.1% Triton-X, followed
by regular immunofluorescence staining procedure.
Immunohistochemistry and image analysis
Anesthetized mice were transcardially perfused with
0.9% saline. Mouse brains were removed and fixed in 4%
paraformaldehyde for 48 h. Fixed brains were cryopre-
served in 30% sucrose in PBS for at least 2 days, and cor-
onal brain sections (30 μm) were obtained with a sliding
microtome. For immunostaining, floating brain sections
were permeabilized and incubated in blocking solution
(10% normal goat serum in 0.3% Triton X-100 TBST) at
room temperature for 1 h. Sections were then incubated
with primary antibodies, including MC1 (1:500), acH3K18
(1: 1000) and Dapi. After overnight incubation, the sections
were incubated with secondary antibodies including Cy3-
labeled donkey anti-rabbit IgG (1:500, Jackson ImmunoRe-
search) and fluorescein-labeled goat anti-mouse IgG (1:500,
Vector Laboratories). Images were acquired by Keyence
BZ-X7000 microscope, and analyzed using ImageJ software
(NIH). Experimenters quantifying immunoreactivity were
blind to the mouse genotype and treatment conditions.
Mice
Mice were housed in a pathogen-free barrier facility with
a 12-h light/dark cycle and ad libitum access to food and
water. All animal procedures were carried out under
guidelines approved by the Institutional Animal Care
and Use Committee of the University of California, San
Francisco. P301ShTau transgenic mice (PS19), Ep300F/F
and CBPF/F mice were purchased from Jackson Labora-
tory. Ep300F/F mice were crossed with CBPF/F mice to
generate Ep300F/F/CBPF/F mice. PS19 mice were crossed
to Ep300F/F/CBPF/F mice to generate P301ShTau/
p300F/+/CBPF/+ mice, which were further crossed with
Ep300F/F/CBPF/F mice to generate P301ShTau/Ep300F/F/
CBPF/F mice. Mice were assigned into gender- and age-
matched treatment groups in a randomized manner
for all experiments. The sample size for each experi-
ment was determined based on previous experiences
with these models.
Stereotaxic injection
Mice were anesthetized with 2% isoflurane by inhal-
ation for the duration of surgery, and secured on a
stereotaxic frame (Kopf Instruments). 3–4-month-old
PS19 mice and non-transgenic control mice were
injected stereotaxically at a rate of 0.5 μl/min, with
equal amounts (1 × 1012 genomic particles) of AAV1
expressing either Cre or GFP control (ViroTek), into
the dentate gyrus of right hippocampus. 2 μL of 3.5
mg/ml synthetic tau fibrils (K18/PL) were injected into
CA1 region of left hippocampus. The following coor-
dinates were used for dentate gyrus (anterior-posterior
− 2.1, medial-lateral − 1.7, dorsal-ventral − 2.1) and
CA1 (anterior-posterior − 2.5, medial-lateral + 2.0,
dorsal-ventral − 1.8). Control animals were injected
with 2 μL of PBS instead of fibrils.
Statistics
Data were analyzed with GraphPad Prism 7 (Graph-
Pad) or Stata. Differences between means were
assessed with paired or unpaired Student’s t test, one-
way or two-way analysis of variance, followed by post
hoc testing of pairwise comparisons among genotypes
(with Tukey’s or Dunnett’s correction for one-way
ANOVA and Bonferroni correction for two-way
ANOVA), as indicated. Pearson’s correlation coeffi-
cients were used to quantify the linear relationship
between two variables. Outliers are pre-established as
data outside of mean ± 2SD. The level of significance
was set as p < 0.05.
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Results
Hyperactive p300/CBP in tauopathy brains is associated
with ALP impairment
To investigate the role of p300/CBP in the pathogenesis
of tauopathies, we first evaluated the activity of p300/
CBP in healthy and diseased brains. Acetylation of the
p300/CBP target –histone H3– at lysine 18 (acH3K18)
[28] was completely absent in p300/CBP double-
knockout primary neurons (Fig. 1a and Additional file 1:
Figure S1A), making it a specific readout for neuronal
p300/CBP activity. ELISA demonstrated significantly
higher acH3K18 in CSF samples from patients with AD
than in healthy controls (Fig. 1b). This increase is signifi-
cantly correlated with CSF levels of p-tau/Aβ42, a diag-
nostic biomarker of AD [29] (Fig. 1c).
AD brains with high tau burden exhibit impaired ALP
and accumulate undegradable autophagic vacuoles
(AVs), which are rare in healthy brains [30–32]. Because
p300 has been reported to regulate autophagy [33, 34],
we investigated the relationship between p300/CBP and
Fig. 1 Hyperactive p300/CBP Is Associated with Impairment in the Autophagy-Lysosomal Pathway in Tauopathy Brains a Representative
immunoblots of p300, CBP, acH3K18, and H3 in lysates of p300F/F/CBPF/F primary neurons infected with lenti-control (ctrl) or lenti-Cre. b Levels of
acH3K18, measured by ELISA, in CSF samples from normal controls (normal, n = 14) and patients with AD (n = 13). ***p < 0.001 by unpaired t test.
Values are mean ± SEM. c Pearson correlation analysis of acH3K18 and CSF p-tau/Aβ42 levels in CSF samples from normal controls (normal, n = 3)
and AD patients (n = 6). d Representative immunoblots of acH3K18, total H3, LC3-I, LC3-II, SQSMT/p62, and GAPDH in hippocampal lysates of 10-
month-old wildtype (WT) and PS19 mice. e–g Levels of acH3K18 relative to total H3 (e), LC3-II (f) and p62 (g) relative to GAPDH, normalized to
WT. h–j Pearson correlation analysis of LC3-II and p62 levels (h), acH3K18 and LC3-II levels (i), and acH3K18 and p62 levels (j). (d–j) n = 7 mice per
group. **p < 0.01, ***p < 0.001 by unpaired t test. Values are mean ± SEM
Chen et al. Molecular Neurodegeneration            (2020) 15:2 Page 6 of 19
ALP impairment in tauopathy. In line with our observa-
tions in human patients, acH3K18 levels were signifi-
cantly higher in the hippocampi of 10-month-old
tauP301S transgenic mice (PS19), a model of tauopathy
[35], than in wild-type (WT) littermates (Fig. 1d and e),
indicating p300/CBP hyperactivity. Such difference was
also observed in 3-month-old PS19 mice and WT litter-
mates (Additional file 1: Figure S1 C and D), and p300/
CBP hyperactivity in PS19 mice maintained at the same
level as the mice age (Additional file 1: Figure S1 E and
F). Levels of autophagosome markers LC3-II and
SQSTM1/p62 were increased in PS19 mice compared to
WT littermates (Fig. 1 d, f and g). Since LC3-II and p62
are degraded in autolysosomes upon autophagosome
maturation, higher steady-state levels of these markers
suggest an accumulation of immature AVs (Fig. 2a),
consistent with previous immuno-electron microscopy
studies [30, 31]. Interestingly, levels of LC3-II and p62
correlate with each other (Fig. 1h), and each correlated
with p300/CBP activity (Fig. 1 i and j), implicating an
underlying relationship between hyperactive p300/CBP
and ALP impairment in tauopathy brains.
p300/CBP inhibits autophagic flux
To directly examine how p300/CBP affects ALP in
neurons, we measured autophagic markers in p300/
CBP double knockout neurons. In neurons with post-
mitotic knockout of p300 and CBP, we observed sig-
nificantly reduced steady-state levels of LC3-I, LC3-II,
and p62 (Fig. 2 b, c, e), suggesting enhanced autopha-
gic flux (Fig. 2a). We measured autophagic flux by
LC3 turnover assay (Fig. 2f). Upon bafilomycin A1
(BafA1) treatment, p300/CBP knockout neurons accu-
mulated more LC3-II from baseline compared to WT
neurons (Fig. 2g, h). Thus, the reduction of steady-
state LC3-II in p300/CBP knockout neurons was due
to enhanced autophagic flux, rather than to reduced
induction of autophagy. In agreement with this, the
conversion of LC3-I to LC3-II was accelerated in p300/
CBP knockout neurons as reflected by the LC3-II/I ratio
(Fig. 2d). We next examined autophagic flux in response
to p300/CBP activation in primary neuronal culture.
Treatment with a small molecule p300/CBP activator
CTB [36] increased p300/CBP activity as expected (Fig.
2j), increased steady-state levels of LC3-II and p62 (Fig. 2
i, k and l), and reduced autophagic flux as measured by
LC3 turnover assay with BafA1 co-treatment (Fig. 2 m and
n). In addition, we used a dual-labeled fluorescent re-
porter, mCherry-GFP-LC3, to monitor the maturation of
AVs [37]. In this system, immature AVs with neutral pH
are yellow since both mCherry and GFP are fluorescent,
whereas mature AVs with acidic pH are red since only
mCherry retains fluorescence (Fig. 2o). In control neurons
expressing mCherry-GFP-LC3, there were more red AVs
than yellow AVs (Fig. 2 p and q), indicating that most
AVs were mature and autophagic flux was normal. In con-
trast, CTB treatment significantly increased the number of
yellow AVs and reduced the number of red AVs (Fig. 2 p
and q), resulting in a reduced red-to-yellow ratio (Fig. 2r).
Similar results were observed in HEK293T cells overex-
pressing p300 and tau: Overexpression of p300 increased
steady-state levels of both LC3-II and p62 (Additional file
1: Figure S2, A and B), and reduced autophagic flux mea-
sured by LC3 turnover assay (Additional file 1: Figure S2,
C and D). In HEK293T cells with mCherry-GFP-LC3 re-
porter, p300 overexpression led to reduced red-to-yellow
ratio (Additional file 1: Figure S2 E–G). The reduction in
the number of AVs in HEK293T cells with p300 overex-
pression might reflect impaired AV formation, in line with
a previous report [33]. The slightly different phenotype be-
tween primary neurons and HEK293T cells is likely due to
differences in cell-type-specific basal levels of autophagy.
Taken together, these data indicate that p300/CBP hyper-
activity inhibits autophagic flux.
p300/CBP promotes tau secretion
Tau is thought to be released through an unconventional
secretion pathway [11, 12], which overlaps with ALP [14,
15, 38]. Because hyperactive p300/CBP impairs ALP and
reduces autophagic flux, we investigated whether p300
hyperactivation affects tau secretion. In HEK293T cells
overexpressing human tau (hTau), extracellular tau was
readily detectable in the conditioned medium and was
largely unphosphorylated (Fig. 3a, 3rd lane), consistent
with previous reports [39, 40]. Co-expression of p300
markedly increased the level of acetylated tau (ac-tau)
and increased intracellular accumulation of total tau (t-
tau) (Fig. 3 a and b), as expected, since hyperacetylation
of tau is known to increase its stability and promote ac-
cumulation [17, 18]. Remarkably, p300 overexpression
also led to significantly increased t-tau secretion (mea-
sured as levels of extracellular tau normalized to intracel-
lular tau) (Fig. 3a and c), and increased the levels of
secreted phosphorylated tau (p-tau, AT8-positive) (Fig. 3a,
4th lane). We then examined how genetic inhibition of
p300/CBP affects tau in neurons. In p300/CBP double-
knockout neurons overexpressing hTau, tau acetylation
was abolished as expected (Fig. 3d), and intracellular t-tau
levels were reduced without affecting tau mRNA levels
(Fig. 3e and f), consistent with decreased protein stability
associated with reduced acetylation [17]. Strikingly, p300/
CBP knockout drastically reduced tau secretion (Fig. 3g),
supporting the conclusion that p300/CBP promotes tau
secretion. Indeed, when neurons were treated with the
p300/CBP activator CTB, both intracellular tau accumula-
tion and extracellular tau secretion were significantly in-
creased (Fig. 3 h and i). Western blot analysis of the
conditioned media showed that CTB treatment increased
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the secretion of not only full-length tau, but also truncated
tau (Additional file 1: Figure S3 A). The increased tau re-
lease mainly resulted from physiological secretion rather
than cell damage or death, as we detected minimal
caspase-3 cleavage and no tubulin release associated with
CTB treatment (Additional file 1: Figure S3, B–D). In
addition, CTB treatment did not alter the secretion of
Aβ40 and Aβ42 (Additional file 1: S3 E and F), suggesting
that p300/CBP activation specifically affects tau secretion.
A new p300 inhibitor reduces tau secretion
Next, we screened 133,000 compounds from UCSF’s
Small Molecule Discovery Center library for small-
molecule inhibitors of p300, using a high-throughput
homogeneous time-resolved fluorescence assay to meas-
ure the acetylation of full-length 2N4R tau by the puri-
fied core domain of p300 in the presence of acetyl-CoA
(Additional file 1: Figure S4 A). Of these compounds,
1120 had inhibition values > 3 SD above the mean and
were not promiscuous pan-assay interference com-
pounds or quenchers of the donor. After validation and
counter-screening to filter out fluorescence interference
compounds, we confirmed 212 hits, of which 28 had an
IC50 < 50 μM and a hillslope < 3. Twenty of the 28 com-
pounds were commercially available and purchased for
retesting (Additional file 1: Figure S4 B). One of the top
hits, 37,892 (Fig. 4a), had an IC50 of 35.3 μM (Fig. 4b).
Orthogonal MMBC assay confirmed its inhibitory activ-
ity (Additional file 1: Figure S4 C). 37892 competed with
tau, as its IC50 values increased with increasing tau con-
centrations (Additional file 1: Figure S4 D). The binding
of 37892 and p300 was determined by differential scan-
ning fluorimetry (Additional file 1: Figure S4 E). In
HEK239T cells, 37892 reduced p300/CBP activity (mea-
sured by acH3K18) in a dose-dependent fashion
(Additional file 1: Figure S4 F, Fig. 4c), and did not in-
duce significant toxicity (Additional file 1: Figure S4G).
We next examined the effects of 37892 on tau homeo-
stasis in human iPSC-derived excitatory neurons [41].
37892 reduced intracellular ac-tau and t-tau accumula-
tion (Fig. 4 d–f), and reduced tau secretion (Fig. 4g). On
the other hand, 37892 increased autophagic flux as mea-
sured by LC3 turnover after co-treatment with BafA1
(Fig. 4 h and i). To determine whether the effect of
37892 on tau secretion is dependent on p300/CBP inhib-
ition, we treated p300/CBP double knockout neurons
with 37892, and failed to see further decrease of tau se-
cretion in the knockout neurons (Fig. 4j). Therefore,
37892 reduces tau secretion through inhibition of p300/
CBP.
Blocking autophagic flux increases tau secretion and
occludes the effects of p300
The correlation between p300/CBP-induced ALP im-
pairment and excessive tau secretion prompted us to in-
vestigate how autophagic flux affects tau secretion. First,
we used BafA1 to block lysosomal degradation and in-
hibit autophagic flux (Fig. 5a). In primary neurons,
BafA1 treatment led to accumulation of LC3-II and p62
as expected (Fig. 5 b–d) [42, 43]. Intracellular tau levels
were increased by BafA1 treatment (Fig. 4e), indicating
that tau is normally degraded by ALP. Remarkably, tau
secretion (after normalization to intracellular tau levels)
was increased by two-fold in this setting (Fig. 4f
Additional file 1: Figure S5 A). The majority of the in-
crease was not due to cell death or increased membrane
permeability, as shown by unaffected lactate dehydro-
genase (LDH) release, minimal caspase-3 cleavage and
undetectable α-tubulin release (Additional file 1: Figure
S5 B-E). Similar effects on tau accumulation and
(See figure on previous page.)
Fig. 2 p300/CBP Inhibits Autophagic Flux in Neurons a Schematic diagram showing autophagic flux with changes in autophagic markers. b–e
p300/CBP double knockout in primary mouse neurons reduces LC3 and p62 accumulation. b Representative immunoblots of LC3-I, −II, p62, and
GAPDH in lysates of p300F/F/CBPF/F primary neurons infected lenti-ctrl or lenti-Cre. c–e Quantification of LC3-II (c), p62 (e) relative to GAPDH, and
LC3-II/I (d), normalized to control. n = 6 wells from three independent experiments. *p < 0.05, ***p < 0.001 by unpaired t test. f Measuring
autophagic flux by LC3 turnover assay. g, h p300/CBP double knockout in primary mouse neurons increases autophagic flux. g Representative
immunoblots of LC3-I, −II and actin in lysates of p300/CBP double knockout neurons that were treated with BafA1 (10 nM) or DMSO for 24 h. h
Quantification of autophagic flux based on the difference (increase) of LC3-II in response to BafA1 treatment, normalized to control (Cre-, BafA1-).
n = 4 wells from two independent experiments. **p < 0.01 by unpaired t test. i–n CTB treatment in primary neurons reduces autophagic flux. i
Representative immunoblot of LC3-I, −II, p62 and actin in lysates of primary mouse neurons treated with DMSO (control) or CTB (50 uM) for 24 h.
j–l Quantification of acH3K18 relative to H3 (j), LC3-II (k) and p62 (l) relative to actin, normalized to control. n = 6 wells from four independent
experiments. *p < 0.05, **p < 0.01 by unpaired t test. m Representative immunoblot of LC3-I, −II and actin in lysates of primary mouse neurons
treated with DMSO (control), CTB (50 uM), BafA1 (10 nM), or CTB + BafA1 for 24 h. n Quantification of autophagic flux by the difference (increase)
of LC3-II in response to BafA1, normalized to control (CTB-, BafA1-). n = 3 wells from three independent experiments. **p < 0.01 by unpaired t test.
o Using mCherry-GFP-LC3 color change to measure autophagic flux. p Representative images of primary mouse neurons infected with lentivirus
expressing mCherry-GFP-LC3 treated with CTB (50 uM) or DMSO (control) for 24 h. Scale bar: 10 μm. q Quantification of autophagic vesicles (AV).
Autophagosomes (APG) are identified as yellow vesicles retaining both mCherry and GFP fluorescence. Autolysosomes (AL) are identified as red
vesicles in which GFP fluorescence is quenched by the low pH in lysosomes. *p < 0.05, ***p < 0.001, two-way ANOVA, Tukey-Kramer post hoc
analysis. r Ratio of the number of red vesicles to yellow vesicles per cell. **p < 0.01, unpaired t test. From two independent experiments, n = 12
cells (control), n = 17 cells (CTB). Values are mean ± SEM
Chen et al. Molecular Neurodegeneration            (2020) 15:2 Page 9 of 19
secretion were observed in primary neurons treated with
a combination of NH4Cl (pH neutralizer) and leupeptin
(inhibitor of lysosomal enzymes) (N/L). (Additional file
1: Figure S5 F–J). Similarly, in human iPSC-derived neu-
rons, treatment with N/L (Additional file 1: Figure S5 K
and L), or vinblastine (Additional file 1: Figure S5M and
N), which inhibits the fusion of autophagosomes with
endosomes and lysosomes [44], promoted secretion of
endogenous hTau. Having established that blocking au-
tophagic flux at late steps of ALP increases tau secretion,
we asked whether the effect of p300/CBP on tau secre-
tion is mediated by its impairment of autophagic flux. In
Fig. 3 p300/CBP Promotes Tau Secretion a–c p300 overexpression in HEK293T cells increases tau secretion. a Representative immunoblot of total
tau (t-tau), phosphor-tau (p-tau, AT8), acetylated tau (ac-tau, K174), and GAPDH in the lysate (5% of total) and conditioned medium (25% of total)
of HEK293T cells transfected with tau alone or tau+p300. HEK293T cells were serum-starved for 48 h after transfection. The conditioned medium
was concentrated 25-fold. b, c Quantification of intracellular total tau (t-tau) levels (b) and t-tau secretion (c), normalized to control. t-tau
secretion was quantified by normalizing extracellular tau to intracellular tau. n = 8 wells from eight independent experiments. *p < 0.05, **p < 0.01
by unpaired t test. d–g p300/CBP double knockout in primary mouse neurons reduces tau secretion. d Representative immunoblot of ac-tau
(K174), t-tau, and GAPDH in the lysate of p300F/F/CBPF/F primary neurons infected with lenti-ctrl or lenti-Cre. e hTau mRNA levels in p300F/F/CBPF/F
primary neurons infected with lenti-ctrl or lenti-Cre, by qRT-PCR. n = 4 wells from two independent experiments. ns, non-significant by unpaired t
test. f Quantification of intracellular t-tau levels by tau ELISA, normalized to control. g Quantification of tau secretion over 3 h by ELISA,
normalized to intracellular tau levels and normalized to control. n = 6 wells from three independent experiments. **p < 0.01, ***p < 0.001, unpaired
t test. h, i CTB treatment increase tau secretion in primary mouse neurons. h Quantification of intracellular total tau levels by tau ELISA,
normalized to control. i Quantification of tau secretion over 3 h by ELISA, normalized to intracellular tau levels and normalized to control. n = 8
wells from four independent experiments. *p < 0.05, **p < 0.01, unpaired t test. Values are mean ± SEM
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primary neurons, CTB or BafA1 treatment each in-
creases tau secretion, and co-treatment with CTB and
BafA1 did not result in an additional increase in tau se-
cretion compared to the case of single treatment (Fig.
5g). Similarly, while p300 overexpression alone and
BafA1 treatment alone both increased tau secretion in
HEK293T, there was no synergistic effect of the combin-
ation (Additional file 1: Figure S5O). Next, we examined
Fig. 4 New p300 Inhibitor 37892 Reduces Tau Secretion (a) Structure of SMDC37892. b 37892 inhibited tau acetylation by p300 with an IC50 of
35 μM. c Concentration-response curve (CRC) for 37892, quantified from p300 activity in HEK293T cells. d–g 37892 treatment in human iPSC-
derived neurons. d Representative immunoblot of ac-tau (K174), t-tau, and GAPDH in lysates of human iPSC-induced neurons treated with DMSO
(control) or 37892 (50 μM) for 3 days. Quantification of levels of ac-tau (e) and intracellular t-tau (f) after 3 days of treatment, normalized to
control. g Quantification of tau secretion over 3 h, normalized to intracellular tau levels, and normalized to control. n = 6 wells from three
independent experiments. *p < 0.05, ***p < 0.001 by unpaired t test. h–j 37892 treatment increases autophagic flux in hTau-expressing mouse
primary neurons. h Representative immunoblots of p62, LC3-II and actin in primary neurons treated with 37892 (50 μM), BafA1 (5 nM), or both, for
24 h. i Autophagic flux in control and 37892-treated neurons quantified from the increase of LC3-II levels in response to BafA1 treatment,
normalized to control. n = 6 wells from three independent experiments. **p < 0.01 by unpaired t test. j Quantification of tau secretion over 3 h in
p300/CBP double knockout neurons treated with 37892. p300F/F/CBPF/F primary neurons were infected with lenti-ctrl or lenti-Cre, and treated with
DMSO (−) or 37892 (50 μM) for 24 h. n = 4 wells from 2 independent experiments. *p < 0.05, ns, non-significant, by one-way ANOVA and Sidak’s
multiple comparisons test. Values are mean ± SEM
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whether the reduction in tau secretion associated with
p300 inhibition is mediated through autophagy. Primary
neurons treated with p300 inhibitor 37892 alone had re-
duced tau secretion, as shown previously (Fig. 5h). When
autophagic flux was blocked by BafA1 co-treatment in
these neurons, the effect of 37892 on tau secretion was
masked by the effect of BafA1 treatment (Fig. 5h). Thus,
blocking autophagic flux by BafA1 completely abolished
the effect of p300 inhibition by 37892 on tau secretion.
These results showed that blocking autophagic flux in-
creases tau secretion and occludes the effects of p300,
suggesting that ALP impairment is downstream of p300/
CBP hyperactivity.
Enhancing autophagy flux mitigates p300-mediated tau
secretion
We next examined if promoting autophagic flux affects tau
secretion. Rapamycin treatment induces autophagic flux by
promoting autophagic induction via mTOR inhibition [45]
and enhancing lysosomal degradation [46] (Fig. 6a), result-
ing in increased LC3-II/I (reflected in reduced LC3-I) and
reduced p62 (Fig. 6b–d). In primary neurons, rapamycin
treatment led to a trend of reduction in intracellular
tau accumulation (Fig. 6e), and significantly reduced
tau secretion (Fig. 6f). Next, we tested whether promot-
ing autophagic flux rescues tau secretion induced by
p300 overexpression in hTau-expressing HEK293T
cells. In the absence of p300 overexpression, rapamycin
enhanced autophagic flux, as indicated by an increased
turnover of LC3-I to LC3-II (reflected in reduced LC3-I
levels) and reduced p62 levels (Fig. 6g, 2nd lane,
Additional file 1: Figure S6 A and B), and reduced tau
secretion (Fig. 6 g and h). In cells overexpressing p300,
enhancing autophagic flux by rapamycin (Additional file 1:
Figure S6 A and B) abrogated the enhanced secretion of tau
(Fig. 6 g and h). Similarly, in primary neurons, enhancing
p300/CBP activity by treating with CTB elevated tau secre-
tion, and this was suppressed by co-treatment with
Fig. 5 Blocking Autophagic Flux Increases Tau Secretion and Occludes the Effects of p300 a Schematic diagram showing autophagic flux and
predicted changes in autophagic markers with baflomycin A1 (BafA1) treatment. b–f BafA1 treatment in primary neurons. b Representative
immunoblots of LC3-I, LC3-II, p62 and actin in lysates of rat primary neurons treated with BafA1 (10 nM) or control (ctrl, DMSO) for 24 h.
Quantification of levels of LC3-II (c) and p62 (d) relative to actin, normalized to control. e Quantification of intracellular tau levels by ELISA,
normalized to control. f Quantification of tau secretion over 3 h by ELISA, normalized to intracellular tau levels and normalized to control. (b–f)
n = 6 wells from three independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by unpaired t test. g Quantification of tau secretion over 3 h in
primary neurons treated with BafA1 (10 nM), CTB (50 μM) or combined, normalized to intracellular tau levels and normalized to control (CTB-
BafA1-). n = 6 wells from three independent experiments. **p < 0.01, *p < 0.05, ns, non-significant by one-way ANOVA and Sidak’s multiple
comparisons test. h Quantification of tau secretion over 3 h in neurons treated with BafA1 (10 nM), 37892 (50 μM) or combined, normalized to
intracellular tau levels and normalized to control (37892- BafA1-). n = 6 wells from three independent experiments. *, #p < 0.05, ***p < 0.001 by
one-way ANOVA and Sidak’s multiple comparisons test. Values are mean ± SEM
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rapamycin (Fig. 6 i and j). Together, these results suggest
that the effect of p300/CBP on tau secretion is mediated by
reduced autophagic flux.
Inhibition of p300/CBP reduces tau spreading
Tau secretion is the first step in the process of intercel-
lular tau transmission and the spread of tau pathology.
To determine whether p300/CBP affects the spread of
pathogenic tau, we used an in vitro model in which syn-
thetic tau fibrils (K18/PL) induce the formation and
intercellular spreading of tau aggregates in primary neu-
rons expressing P301S hTau [27]. This seeding-based
assay reflects both the initial seeding by tau fibrils and
the secondary seeding (propagation) by tau secreted
from neurons [27]. MC1 immunostaining is used to de-
tect the pathological, aggregated conformation of tau
Fig. 6 Enhancing Autophagy Flux Mitigates p300-mediated Tau Secretion a Schematic diagram showing autophagic flux and predicted changes
in autophagic markers with rapamycin (rapa) treatment. b–f Rapa treatment in primary neurons. b Representative immunoblots of LC3-I, LC3-II,
p62 and actin in lysates of rat primary neurons treated with rapa (0.25 μM) or DMSO (ctrl) for 24 h. Quantification of levels of LC3-II/I (c) and p62
(d) relative to actin, normalized to control. e Quantification of intracellular tau levels by ELISA, normalized to control. f Quantification of tau
secretion over 3 h by ELISA, normalized to intracellular tau levels and normalized to control. (b–f) n = 6 wells from three independent
experiments. ***p < 0.001, **p < 0.01 by unpaired t test. g, h Rapamycin treatment in HEK293T cells with and without p300 overexpression. g
Representative immunoblots of LC3-I, LC3-II, p62, total tau (t-tau) and GAPDH in lysate and conditioned medium of HEK293T cells transfected
with tau alone or tau+p300. Serum-starved HEK293T cells were treated with DMSO (ctrl) or rapamycin (1 μM) for 24 h. h Quantification of t-tau
secretion in (g) normalized to intracellular levels and normalized to control. n = 3 wells from three independent experiments. *, #p < 0.05 by one-
way ANOVA and Sidak’s multiple comparisons test. i, j Primary neurons treated with CTB and rapa. i Representative immunoblots of LC3-I, LC3-II,
p62, and actin in lysates of mouse primary neurons treated with DMSO (ctrl), CTB (50 μM), rapa (0.25 μM) and CTB + rapa. j Quantification of tau
secretion over 3 h by ELISA of neurons as in (i), normalized to intracellular tau levels and normalized to control (CTB- rapa-). n = 6 wells from three
independent experiments. *, #p < 0.05, **p < 0.01 by one-way ANOVA and Sidak’s multiple comparisons test. Values are mean ± SEM
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[47] (Fig. 7a). Double knockout of p300/CBP markedly
reduced the number of neurons bearing MC1-positive tau
aggregates without affecting neuron number (Fig. 7a–c).
Reduced MC1 signal was also observed in p300/CBP
double heterozygous neurons, in the absence of changes
in neuron number and neurite length (Additional file 1:
Figure S7 A–E). A similar effect was observed in primary
neurons treated with 37892 (Additional file 1: Figure S7
F–I). Thus, inhibiting p300/CBP reduces seed-induced tau
pathology in vitro.
To determine whether p300/CBP inhibition reduces
tau spreading in vivo, we simultaneously injected tau fi-
brils into the left hippocampus (CA1) and AAV-Cre or
AAV-GFP into the right hippocampus (dentate gyrus) of
4–5-month-old (mo) PS19 mice carrying p300F/F and
CBPF/F (Fig. 7d). Deletion of p300/CBP in the right hippo-
campus resulted in reduced staining for acH3K18 (Fig. 7 e
and f). Consistent with previous studies [4], injection of
tau fibrils markedly increased MC1-positive tau pathology
in the ipsilateral and contralateral hippocampi within 4
weeks in PS19 mice expressing AAV-GFP (Fig. 7g). Non-
transgenic littermates injected with tau fibrils did not have
detectable MC1 signal in 4 weeks (Additional file 1: Figure
S8 A). In PS19 mice, Cre-mediated p300/CBP deletion sig-
nificantly reduced the spread of MC1-positive tau to the
contralateral hippocampus and cortex (Fig. 7g, h, j, Add-
itional file 1: Figure S8 B and C). Remarkably, the extent
of tau spreading quantified by MC1 positivity correlated
with p300/CBP activity in AAV-injected hippocampus,
measured by acH3K18 signal (Fig. 7 i and k). Thus, inhib-
ition of p300/CBP has the potential to reduce the spread
of tau pathology in vivo.
Discussion
Our study shows that p300/CBP acetyltransferase activ-
ity is aberrantly increased in tauopathy in humans and
mice, and correlates with ALP impairment. In primary
neurons and human iPSC-derived neurons, inhibition of
p300/CBP enhanced autophagic flux and suppressed tau
secretion, and activating p300/CBP had the inverse ef-
fect. Moreover, p300/CBP inhibition strongly reduced
the pathogenic spread of tau inclusions in vivo.
Through detailed mechanistic dissections, we showed
that p300/CBP promotes tau secretion by inhibiting
autophagic flux. These findings establish a novel con-
nection between p300/CBP-mediated ALP impairment
and tau propagation.
p300/CBP, best known as transcriptional cofactor, was
found to be a master regulator of AD progression, re-
vealed in an unbiased system approach analysis of gene
expression profiles from laser-captured neurons from
AD and controls subjects [16]. Indeed, we found the
levels of acetylated H3K18, the canonical substrate of
p300, are increased in the CSF of patients with AD,
consistent with elevated p300 activity as previously re-
ported [16, 48]. Interestingly, other acetylation sites that
are independent of p300/CBP, such as H4K16 [28], were
found to be reduced in AD brain [49], highlighting the
specific elevation of histone acetylation that depends on
p300/CBP activity. How p300/CBP becomes hyperactive
in diseased brains is unclear. We found that p300/CBP
activity is increased in 3 mo PS19 mice compared with
their wild-type littermates, suggesting that hyperactivity
of p300/CBP is an early event in tauopathy, before the
accumulation of insoluble tau. p300/CBP hyperactivity
in turn enhances tau accumulation, secretion and
spreading, resulting in a feedforward vicious cycle.
Tau homeostasis requires degradation by the UPS and
ALP (reviewed in [6]). Here, we found that elevated
p300/CBP activities correlated with ALP impairment in
mice with tauopathy. Autophagy-mediated tau degrad-
ation is known to be inhibited by pathogenic tau point
mutations (P301L, A152T) and post-translational modifi-
cations [50]. Furthermore, autophagic and endolysosomal
dysfunction is accompanied by accumulation of immature
AVs in the brains of AD patients [16, 30, 32, 51]. Our
findings implicate p300/CBP hyperactivity as a key player
in the impairment of autophagic flux that slows the turn-
over of AVs through lysosomal degradation. Previous
studies showed that p300 acetylates the autophagy com-
ponents Atg5, Atg7, Atg8, and Atg12, and that knock-
down of p300 reduces p62 levels and increases LC3-II
levels in Hela cells [33]. In neurons, we showed that p300/
CBP knockout reduced p62 levels and increased ratio of
LC3-II/I ratio, similar to Hela cells and fully consistent
with increased autophagy flux. However, different from
that in Hela cells, p300/CBP knockout in neurons resulted
in reduced total LC3 (including LC3-I and LC3-II) levels.
This discrepancy is likely due to differences in basal levels
of autophagy in cancer cell lines versus postmitotic cells,
such as neurons. Indeed, neurons have been shown to
exhibit more efficient clearance of newly forming
autophagosomes by lysosomes [31]. In addition, p300/
CBP activation results in accumulation of LC3 and p62,
suggesting a blockage in late stage ALP. Together, our
results suggest that p300/CBP reduces autophagic flux
at both the induction stage and maturation/degradation
stage (Fig. 6a).
We showed that p300/CBP activation promotes tau se-
cretion, likely via inhibition of ALP. Blocking lysosomal
degradation or the fusion of autophagosomes with lyso-
somes markedly increased tau secretion, whereas pro-
moting autophagic flux with rapamycin reduced tau
secretion. Thus, tau secretion could be an alternative
clearance mechanism to maintain overall cellular pro-
teostasis when degradative pathways are impaired or
overloaded. We found that increasing autophagic flux
mitigates tau secretion in cells with enhanced p300/CBP
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activity, and blocking autophagic flux abolished the
beneficial effect of p300/CBP inhibition. These findings
provide strong evidence that the effects of p300/CBP on
tau secretion are mediated via its modulation of ALP.
How does p300/CBP hyperactivation inhibit ALP and
promotes tau secretion? It was recently reported that
p300-mediated acetylation of beclin 1, VPS34, and SIK2
inhibits autophagy initiation, autophagosome matur-
ation, and endocytic trafficking [34, 52, 53], suggesting
that these proteins may play a role in regulating secre-
tion of tau and potentially other proteins. Secondly, as
p300/CBP regulates histone acetylation, the mechanism
could also involve epigenetic changes in the autophagy-
relevant transcriptome and synaptic plasticity [21, 54, 55].
Finally, acetylation of tau itself by p300/CBP increases tau
toxicity, which could lead to cell damage such as impaired
cytoskeleton stability and membrane integrity, and in turn
contribute to elevated secretion.
The cellular trafficking through which tau is secreted
is unknown. Secretion of other proteins have been at-
tributed to autophagy-mediated unconventional secre-
tion pathway without the involvement of Golgi-ER
complex, such as IL1β [14, 15]. In Parkinson’s disease,
α-synuclein is secreted through a similar mechanism, in
which accumulated autophagic intermediates such as
autophagosome, autolysosome and multivesicular bodies
(MVBs) fuse with the plasma membrane and release α-
synuclein [56]. We found that increased tau secretion is
associated with accumulation of LC3-II and p62, markers
of intermediate AVs. However, it was previously reported
that LC3-labeled autophagosomes do not appear to be
enriched in tau [38], and indeed we found tau inclusions
largely reside in the cytosol without specific colocalization
with a certain type of autophagic vesicles. In addition,
Atg5 knockout neurons, which lack LC3-II-positive autop-
hagosomes, secrete even more tau (data not shown), sug-
gesting that autophagosomes are not the (only) vesicles
responsible for tau secretion. In Atg5 knockout neurons,
autophagosomes do not form, imposing a heavier tau
burden for other vesicles in ALP such as MVB, late endo-
somes and lysosomes, which could lead to increased tau
secretion. Indeed, tau has been found in exosomes isolated
from cultured neurons and CSF, implicating an MVB-
mediated release mechanism in tau secretion [10, 57]. It
was also reported that Rab7A, a small GTPase involved in
endosomal trafficking, regulates tau secretion, indicating
that a late endosomal compartment is involved [58]. Fi-
nally, as the last step in ALP, lysosomes can undergo exo-
cytosis, a process resembling synaptic vesicle release
regulated by TFEB [59], which could also mediate tau
secretion when autophagy is impaired. In support of the
hypothesis that later-stage intermediate vesicles in ALP
mediate tau secretion, we and others [16] found
accumulation of GVB-like structures with molecular
signature of late endosome and lysosome in P301S hTau
transgenic mouse brain (data not shown).
Pathogenic tau species could differ in their effects on
different autophagy pathways (macroautophagy, chaperone-
mediated macroautophagy and endosomal microautophagy)
[50], and there is complex crosstalk between autophagy
pathways and endolysosomal pathways [60]. For example,
autophagy induction promotes the fusion of MVBs with ly-
sosomes and inhibits exosome release [61]. It was recently
found that rapamycin induces autophagic flux via TRPML1-
TFEB pathway on lysosomes, independent of mTORC-
ULK1 inhibition [46]. In line with this, we found that rapa-
mycin induces autophagic flux and reduces tau secretion,
both in WT cells and in cells with p300 activation. Thus,
fine-tuning of ALP at multiple steps can push the system to
reach a new balance between degradation and secretion of
the cargo.
Increased secretion of tau into the extracellular space
could underlie tau propagation to different brain areas,
the spread of pathology, and disease progression. Here
we showed that p300/CBP inhibition reduced both en-
dogenous tau accumulation and the spread of aggregated
tau pathology. Promoting autophagy by rapamycin re-
duces tau pathology in mouse models [62, 63] and reduces
(See figure on previous page.)
Fig. 7 Inhibition of p300/CBP Reduces Tau Spreading a–c p300/CBP double knockout reduces fibril-induced tau spreading in primary neurons. a
Representative immunofluorescence staining with MC1 and MAP2 antibody in p300F/F/CBPF/F primary neurons infected with AAV-P301S hTau and
lenti-ctrl or lenti-Cre, and treated with synthetic tau fibrils (K18/PL, 100 nM). Negative controls (PBS-treated, AAV non-infected) are included. Scale
bar: 100 μm. b Percentage of MC1-positive neurons, normalized to control. ***p < 0.001, unpaired t test. c Number of valid (live) nuclei,
normalized to control. n = 9 wells from two independent experiments. d–k Inhibition of p300/CBP reduces tau spreading in PS19 mice. d
Schematic diagram of stereotaxic injections in the hippocampus of 3–4 mo PS19 mice carrying p300F/F/CBPF/F. Tau fibrils (K18/PL) were injected
into left CA1 (seeding side). AAV-Cre or AAV-GFP were injected into right dentate gyrus (spreading side). e Representative images of
immunostaining with acH3K18 antibody in the hippocampus after AAV-GFP (control) and AAV-Cre injections. Scale bar: 200 μm. f Quantification
of acH3K18-positive area (normalized to Hoechst) on the spreading side (AAV-injected) normalized to the seeding (fibril-injected) side of
hippocampus. g Representative images of immunostaining of MC1 in the hippocampus (CA3) and cortex (entorhinal) after AAV-GFP and AAV-Cre
injections. Scale bar: 250 μm. h, j Quantification of MC1-positive area of hippocampus (h) and cortex (j) on the spreading side (AAV-injected)
normalized to the seeding (fibril-injected) side. i, k Pearson correlation analysis of acH3K18 signal in the AAV-injected hippocampus with MC1
signal in the hippocampus (i) and cortex (k). n = 7 slices from 9 (AAV-GFP) or 8 (AAV-Cre) mice per group. (f, h, j) ***p < 0.001, unpaired t test.
Values are means ± SEM
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tau spreading in a seeding based cellular assay of tauopa-
thy [64]. Our results suggest that inhibition of p300/CBP
promotes autophagic flux, enhances tau degradation and
reduces tau secretion, thereby attenuating tau spreading.
p300/CBP inhibition also reduces tau acetylation, which in
turn enhances tau clearance and reduces tau accumula-
tion. Thus, the attenuated spread of tau pathology we
observed with inhibition of p300/CBP likely resulted from
reduction of both intracellular tau accumulation and
extracellular tau secretion. Tau propagation is thought to
be caused by soluble tau species, either monomeric or
oligomeric [65, 66]. However, it remains to be determined
whether p300/CBP affects posttranslational modification
of transmitted tau species, or tau seed uptake. In addition,
p300/CBP’s other effects on neurons [21], including neur-
onal plasticity [55, 67] could also indirectly contribute to
modulation of tau spreading. Finally, glial cells may con-
tribute to tau spreading [68], and the p300/CBP-autoph-
agy pathway could also be involved in these cells.
Conclusions
In summary, our findings that p300/CBP hyperactivity im-
pairs ALP, promotes tau secretion and pathogenic propaga-
tion, supports targeting p300/CBP-ALP as a novel strategy to
enhance autophagy and to counteract tau pathogenesis. To
this end, we performed an HTS for new p300 inhibitors in
the context of tau, and identified a new compound that re-
duces tau acetylation and accumulation, and in the
meantime, enhances ALP and reduces tau secretion and
propagation. The in vivo efficacy and further development of
this compound warrants future investigation.
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